GlassScriptPhysician profile
Teri Lynn Smith
NPI 1497735120
$13,866.29
in general payments reported to CMS, 2019-2025
43 companies · $3,806 in 2025
The $3,806 reported for 2025 was more than what 98% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,568 · 2022: $2,239 · 2023: $2,833 · 2024: $3,420 · 2025: $3,806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,026.92 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,860.43 | 2021-2025 | |
| Mdd US Operations, LLC | $1,045.23 | 2022-2025 | Gocovri, Apokyn, Myobloc |
| Biogen, INC. | $990.95 | 2021-2025 | Vumerity, Spinraza, Qalsody |
| Novartis Pharmaceuticals Corporation | $838.63 | 2021-2025 | |
| Pfizer INC. | $804.12 | 2023-2025 | |
| Sk Life Science, INC. | $773.63 | 2021-2025 | Xcopri |
| Amneal Pharmaceuticals LLC | $736.70 | 2021-2025 | Rytary, Crexont, Lyvispah |
| Ucb, INC. | $677.62 | 2021-2025 | Zilbrysq, Rystiggo, Nayzilam |
| Lundbeck LLC | $543.69 | 2021-2025 | Vyepti, Rexulti |
| Lilly USA, LLC | $528.03 | 2021-2025 | Amyvid, Kisunla, Emgality |
| Amgen INC. | $525.76 | 2021-2025 | Uplizna, Aimovig |
| Alexion Pharmaceuticals, INC. | $471.53 | 2021-2025 | Ultomiris, Soliris |
| Emd Serono, INC. | $444.51 | 2023-2025 | Mavenclad |
| Kyowa Kirin, INC. | $406.60 | 2021-2024 | Nourianz |
| Argenx US, INC. | $378.15 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teri Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.